RAPPHealthcare · BiotechnologyThe 16 Wall Street analysts covering Rapport Therapeutics, Inc. hold a median 12-month price target of $68 — +156.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 22 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Rapport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (78): The shares have been drifting up relative to others.
Growth (29): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RAPP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +156.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | Guggenheim | Maintains | Buy | $65 → $70 |
| 21 Oct 2026 | Jones Trading | Maintains | Buy | $50 → $82 |
| 21 Oct 2026 | Wells Fargo | Maintains | Overweight | $51 → $50 |
| 20 Oct 2026 | BTIG | Maintains | Buy | $75 → $89 |
| 20 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $66 |
| 15 Oct 2026 | UBS | Initiates | Buy | $71 |
| 15 Oct 2026 | Wolfe Research | Initiates | Outperform | $50 |
| 6 Oct 2026 | Guggenheim | Initiates | Buy | $65 |
| 6 Oct 2026 | Guggenheim | Initiates | Buy | — |
| 16 Sept 2026 | BTIG | Maintains | Buy | — |
| 16 Sept 2026 | BTIG | Maintains | Buy | $65 → $75 |
| 19 Aug 2026 | BTIG | Reiterates | Buy | $65 |
| 19 Aug 2026 | BTIG | Reiterates | Buy | — |
| 12 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $66 |
| 12 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Aug 2026 | BTIG | Reiterates | Buy | $65 |
| 5 Aug 2026 | BTIG | Reiterates | Buy | — |
| 16 July 2026 | BTIG | Reiterates | Buy | $65 |
| 16 July 2026 | BTIG | Reiterates | Buy | — |
| 24 June 2026 | Leerink Partners | Initiates | Outperform | $52 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RAPP appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Rapport Therapeutics, Inc. returned +6.5% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 5% of US stocks
Cheaper than 31% of US stocks
Cheaper than 81% of US stocks
Higher than 1% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rapport Therapeutics, Inc. has a market value of $1.3B and an enterprise value of $846.9M.
Revenue in the twelve months to 30 June 2026: $20.0M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$137.2M, a −685.8% net margin.
Diluted earnings per share, trailing twelve months: $−3.04.
Free cash flow in the twelve months to 30 June 2026: −$97.1M.
Rapport Therapeutics, Inc. spent $5K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 21.2×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rapport Therapeutics, Inc. employs 84 people — $238K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rapport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rapport Therapeutics discussed Phase II bipolar mania trial results and provided a business update in a Seeking Alpha transcript.
Why it matters — The transcript concerns clinical-trial results and company operations that RAPP watchers may want to follow.
Rapport Therapeutics shares were trading higher on Tuesday, with premarket volume of 1.439 million compared with an average volume of 351.078 thousand, according to Benzinga Pro.
Why it matters — The higher trading and premarket volume are relevant to RAPP watchers tracking the stock’s market activity.
Positive trial data for Rapport Therapeutics’ lead candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak-sales opportunity, according to Jefferies.
Why it matters — The trial data and cited sales potential are relevant to RAPP watchers evaluating the company’s lead pipeline candidate.
Rapport Therapeutics shares rose Tuesday after the company reported promising but mixed test results for its bipolar treatment.
Why it matters — The results are a notable update for RAPP watchers tracking the progress of its bipolar treatment.
Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for bipolar mania. The trial met its primary and secondary endpoints, showing statistically significant placebo-adjusted improvements at Week 3 in YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024).
Why it matters — The results provide RAPP watchers an update on clinical progress for RAP-219 in bipolar mania.
The 16 Wall Street analysts covering Rapport Therapeutics, Inc. have a median 12-month price target of $68, with estimates ranging from $51 to $91. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Rapport Therapeutics, Inc., 16 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapport Therapeutics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, Rapport Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (78 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +156.3% from the last close, and Ticker Nerd's factor model ranks Rapport Therapeutics, Inc. 46 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rapport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RAPP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $51 to $91 over the next 12 months.
Rapport Therapeutics, Inc. returned +6.5% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders.
The most recent item we track (Seeking Alpha, 20 Oct 2026): "Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript". Rapport Therapeutics discussed Phase II bipolar mania trial results and provided a business update in a Seeking Alpha transcript.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders. The company’s work centers on precision neuroscience, using its RAP technology platform to target receptor-associated proteins that help regulate neuronal signaling. Its pipeline includes investigational programs for focal epilepsy, peripheral neuropathic pain, bipolar disorder, chronic pain, migraine, and hearing or vestibular disorders. Rapport Therapeutics also develops receptor-targeted candidates in areas such as AMPA receptor modulation and nicotinic acetylcholine receptor biology, reflecting a broad research effort across neurological and psychiatric conditions. Headquartered in Boston, Massachusetts, Rapport Therapeutics plays a specialized role in the biotechnology market by advancing targeted therapies designed for complex brain and nervous system diseases.
CEO Mr. Abraham N. Ceesay M.B.A. · 84 employees · United States · https://www.rapportrx.com
